Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Owonikoko, Taofeek K.; Kim, H.R.; Govindan, Ramaswamy; Ready, Neal; Reck, Martin; Peters, Solange; Dakhil, Shaker R.; Navarro, Alejandro; Rodríguez-Cid, Jerónimo Rafael; Schenker, Michael; Lee, J.S.; Gutiérrez, V.; Percent, Ivor; Morgensztern, Daniel; Fairchild, Justin; Baudelet, Christine; Park, K.

doi:10.1093/annonc/mdz094

Cited by 85 publications

(77 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mPFS was 1.9 vs. 1.7 vs. 1.4 months in the nivolumab, nivolumab plus ipilimumab, and placebo arms, respectively. However, in the nivolumab plus ipilimumab arm, there was a higher rate of Grade 3-4 adverse events (52%), of discontinuations due to toxicity (31%), and of treatment-related deaths (2.5%) compared to the other arms [55].…”

Section: Sclc First Line and Maintenancementioning

confidence: 87%

Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia

Maggio

Manuzzi

Ricci

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: Neuroendocrine neoplasms are rare entities consisting of a heterogeneous group of tumors that can originate from neuroendocrine cells present in the whole body. Their different behavior, metastatic potential, and prognosis are highly variable, depending on site of origin, grade of differentiation, and proliferative index. The aim of our work is to summarize the current knowledge of immunotherapy in different neuroendocrine neoplasms and its implication in clinical practice. Results: Several studies evaluated the efficacy and safety of immunotherapy in neuroendocrine neoplasms, in any setting of treatment, alone or in combination. Studies led to approval in neuroendocrine neoplasia of the lung, in combination with chemotherapy as first-line treatment or as a single-agent in a third-line setting, and Merkel cell carcinoma as a single agent. Results in other settings have been disappointing so far. Conclusions: Immunotherapy seems a valid treatment option for high grade, poorly differentiated neoplasms. Future trials should explore the combination of immunotherapy with other agents, such as anti-angiogenic or other immunotherapy agents, in order to evaluate potential efficacy in low and intermediate grades, well differentiated tumors.

show abstract

Section: Sclc First Line and Maintenancementioning

confidence: 87%

Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia

Maggio

Manuzzi

Ricci

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…3 Existing and accumulating evidence regarding the use of immune checkpoint inhibitors has suggested that achieving optimal outcomes for these patients will necessitate incorporation of immune checkpoint inhibitors early in the treatment course. Studies of immune checkpoint inhibitors in the maintenance setting (ie, after initial platinum doublet chemotherapy) 7,8 or in the second-line setting 6,9 have failed to show improvements in overall survivalalthough in those patients achieving a response, disease control has generally been more durable than that historically seen with cytotoxic chemotherapy regimens.…”

Section: Discussionmentioning

confidence: 99%

Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis

Widick

Gill

Mantia

et al. 2020

Clinical Lung Cancer

View full text Add to dashboard Cite

“…CheckMate-451 included 834 patients with ES-SCLC who had an ongoing response or stable disease after four cycles of platinum-based chemotherapy. 96 Patients were randomized 1:1:1 to receive maintenance nivolumab alone, nivolumab plus ipilimumab, or placebo. The study did not meet its primary endpoint.…”

Section: Relapsed/refractory Sclc: Immune-checkpoint Inhibition (Io)mentioning

confidence: 99%

Small Cell Lung Cancer: Advances in Diagnosis and Management

Chauhan

Liu

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a late stage. Surgery plays a very small role in this cancer, and management typically involves chemotherapy, delivered with thoracic radiation in early-stage disease. Platinum-based chemotherapy is initially very effective, inducing rapid and often deep responses. These responses, though, are transient, and upon relapse, SCLC is highly refractory to therapy. Immunotherapy has shown promise in delivering meaningful, durable responses and the addition of immunotherapy to first-line chemotherapy has led to the first improvements in survival in decades. Still, the disease remains difficult to manage. Incorporating radiation therapy at specific points in patient management may improve disease control. The development of predictive biomarkers and novel targeted therapies will hopefully improve options for patients in the near future. This review focuses on the current standards of care and future directions.

show abstract

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Cited by 85 publications

References 0 publications

Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia

Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia

Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis

Small Cell Lung Cancer: Advances in Diagnosis and Management

Contact Info

Product

Resources

About